Announcement • May 17
Endo International plc to Report Q1, 2024 Results on May 30, 2024 Endo International plc announced that they will report Q1, 2024 results on May 30, 2024 Announcement • Nov 07
Endo International plc to Report Q3, 2023 Results on Nov 06, 2023 Endo International plc announced that they will report Q3, 2023 results at 4:15 PM, US Eastern Standard Time on Nov 06, 2023 Announcement • Aug 16
Endo International plc, Annual General Meeting, Sep 07, 2023 Endo International plc, Annual General Meeting, Sep 07, 2023, at 12:00 Coordinated Universal Time. Location: First Floor, Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4 Ireland Agenda: To re-elect, by separate resolutions, the following eight members to our Board of Directors to serve until the next Annual Meeting of Shareholders; and to approve the selection of PricewaterhouseCoopers LLP as company's independent registered public accounting firm for the year ending December 31, 2023 and to authorize the Board of Directors, acting through the Audit & Finance Committee, to determine the independent registered public accounting firm’s remuneration. Announcement • Jun 28
Endo International plc Announces First Patient Enrolled in Registry of Dupuytren's Contracture Endo International plc announced that the first patient has been enrolled in GRASP-DC (Generating Real-world Ambispective data to Study participant Treatment outcomes for Dupuytren's Contracture), a non-interventional registry of up to 1,000 patients with Dupuytren's contracture (DC). This registry will create the largest and most comprehensive collection of real-world DC data on treatment outcomes. DC is a progressive hand condition that results in the formation of a collagen rope-like cord that pulls fingers toward the palm and affects an estimated 14 million Americans. The Study is run by a steering committee that consists of Endo, Pulse Infoframe and Drs. Philip Blazar, Gary Pess and James Verheyden. About the Study GRASP-DC (NCT05877066) is a non-interventional study of up to 1,000 DC patients from 15 sites who have initiated treatment within two weeks before, at or any time after the date of enrollment. Patients will be followed for up to three years, and data will be collected from both the patients and their healthcare providers. Patients will answer questions related to, but not limited to, quality of life, reasons for treatment choices, functional outcomes, activities before and after treatment, treatment satisfaction and self-reported treatment effectiveness. Healthcare providers will answer questions related to, but not limited to, the reason for treatment choice; details of contracture size, location and number of cords treated; active and passive range of motion before and after treatment; and treatment techniques used. Announcement • Jun 13
Endo International plc Launches PREVDUO (Neostigmine Mylsulfate and Glycopyrrolate Injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe Endo International plc announced that's Par Sterilele Products business has begun shipping PREVDUO(TM) (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe, the first and only FDA-approved neostigmine--glycopyrrolate combination product in the U.S. Both neostigmine methylsulfates and glycopyrrolate have been approved in the U.S. as single, active ingredient drug products. Neostigmine is always administered in conjunction with glycopyrrolate and, until now, its administration has required two syringes. In April, Endo executed an agreement with Slayback Pharma LLC to distribute PREVDUO(TM), on an exclusive basis in the U.S. Ready-to-use, or RTU, products streamline operations for hospitals by eliminating the need to prepare or transfer the product before patient administration. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, the outcome of the Company's contingency planning and restructuring activities; the timing, impact or results of any pending or future litigation, investigations, proceedings or claims, including opioid, tax and antitrust related matters; any actual or contingent liabilities; settlement discussions or negotiations; the Company's liquidity, financial performance, cash position and operations; the risks and uncertainties associated with chapter 11 proceedings; the time, terms and ability to confirm a sale of the Company's businesses under Section 363 of the U.S. Bankruptcy Code; the risk that the Company's chapter 11 cases may be converted to cases under chapter 7 of the Bankruptcy Code; the adequacy of the capital resources of the Company's businesses and the difficulty in forecasting the liquidity requirements of the operations of the Company's businesses; the unpredictability of the Company's financial results; the Company's ability to discharge claims in chapter 11 proceedings; negotiations with the holders of the Company's indebtedness and its trade creditors and other significant creditors; the risks and uncertainties with performing under the terms of the restructuring support agreement and any other arrangement with lenders or creditors while in chapter 11 proceedings; the performance, including the approval, introduction, and consumer and physician acceptance of new products and the continuing acceptance of currently marketed products; and the Company's ability to obtain and successfully manufacture, maintain and distribute a sufficient supply of products to meet market demand in a timely manner. Reported Earnings • Aug 11
Second quarter 2022 earnings released: US$8.00 loss per share (vs US$0.044 loss in 2Q 2021) Second quarter 2022 results: US$8.00 loss per share (down from US$0.044 loss in 2Q 2021). Revenue: US$569.1m (down 20% from 2Q 2021). Net loss: US$1.88b (loss widened US$1.87b from 2Q 2021). Over the next year, revenue is expected to shrink by 19% compared to a 16% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 44% per year, which means it has not declined as severely as earnings. Reported Earnings • May 06
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2022 results: US$0.28 loss per share (down from US$0.20 profit in 1Q 2021). Revenue: US$652.3m (down 9.1% from 1Q 2021). Net loss: US$65.3m (down 239% from profit in 1Q 2021). Revenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is expected to shrink by 12% compared to a 7.6% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings. Price Target Changed • Apr 27
Price target decreased to US$2.63 Down from US$5.33, the current price target is an average from 5 analysts. New target price is 23% above last closing price of US$2.14. Stock is down 65% over the past year. The company posted a net loss per share of US$2.44 last year. Reported Earnings • Mar 02
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: US$2.44 loss per share (down from US$1.08 profit in FY 2020). Revenue: US$2.99b (up 3.1% from FY 2020). Net loss: US$569.1m (down 330% from profit in FY 2020). Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is expected to shrink by 6.8% compared to a 21% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Price Target Changed • Dec 23
Price target decreased to US$6.17 Down from US$6.86, the current price target is an average from 8 analysts. New target price is 49% above last closing price of US$4.13. Stock is down 29% over the past year. The company is forecast to post earnings per share of US$1.38 for next year compared to US$1.08 last year. Valuation Update With 7 Day Price Move • Dec 15
Investor sentiment deteriorated over the past week After last week's 19% share price decline to US$4.27, the stock trades at a forward P/E ratio of 3x. Average forward P/E is 14x in the Pharmaceuticals industry in the US. Total loss to shareholders of 54% over the past three years. Reported Earnings • Nov 05
Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.30 loss in 3Q 2020) The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$772.0m (up 22% from 3Q 2020). Net loss: US$49.3m (loss narrowed 28% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Nov 02
Investor sentiment improved over the past week After last week's 16% share price gain to US$5.09, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 19x in the Pharmaceuticals industry in the US. Total loss to shareholders of 70% over the past three years. Valuation Update With 7 Day Price Move • Oct 12
Investor sentiment improved over the past week After last week's 20% share price gain to US$4.17, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 20x in the Pharmaceuticals industry in the US. Total loss to shareholders of 77% over the past three years. Valuation Update With 7 Day Price Move • Sep 28
Investor sentiment improved over the past week After last week's 24% share price gain to US$3.40, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 20x in the Pharmaceuticals industry in the US. Total loss to shareholders of 80% over the past three years. Valuation Update With 7 Day Price Move • Sep 10
Investor sentiment improved over the past week After last week's 16% share price gain to US$2.79, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 21x in the Pharmaceuticals industry in the US. Total loss to shareholders of 82% over the past three years. Price Target Changed • Sep 01
Price target decreased to US$6.57 Down from US$7.57, the current price target is an average from 9 analysts. New target price is 213% above last closing price of US$2.10. Stock is down 27% over the past year. Valuation Update With 7 Day Price Move • Aug 20
Investor sentiment deteriorated over the past week After last week's 46% share price decline to US$2.13, the stock trades at a forward P/E ratio of 4x. Average forward P/E is 20x in the Pharmaceuticals industry in the US. Total loss to shareholders of 86% over the past three years. Major Estimate Revision • Aug 13
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$2.73b to US$2.76b. EPS estimate fell from US$1.12 to US$0.61 per share. Net income forecast to shrink 41% next year vs 14% growth forecast for Pharmaceuticals industry in the US . Consensus price target down from US$7.63 to US$7.25. Share price fell 12% to US$4.14 over the past week. Reported Earnings • Aug 06
Second quarter 2021 earnings released: US$0.044 loss per share (vs US$0.077 profit in 2Q 2020) The company reported a soft second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: US$713.8m (up 3.8% from 2Q 2020). Net loss: US$10.2m (down 158% from profit in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jul 23
Investor sentiment improved over the past week After last week's 40% share price gain to US$4.89, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 20x in the Pharmaceuticals industry in the US. Total loss to shareholders of 60% over the past three years. Valuation Update With 7 Day Price Move • Jul 08
Investor sentiment deteriorated over the past week After last week's 17% share price decline to US$3.90, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 20x in the Pharmaceuticals industry in the US. Total loss to shareholders of 64% over the past three years. Executive Departure • Jun 15
Chairman Paul Campanelli has left the company On the 10th of June, Paul Campanelli's tenure as Chairman ended after 1.6 years in the role. As of March 2021, Paul still personally held 1.27m shares (US$9.4m worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 2.38 years. Executive Departure • Jun 15
Senior Independent Director Roger Kimmel has left the company On the 10th of June, Roger Kimmel's tenure as Senior Independent Director ended after 7.3 years in the role. As of March 2021, Roger still personally held 201.50k shares (US$746k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 2.38 years. Valuation Update With 7 Day Price Move • Jun 12
Investor sentiment improved over the past week After last week's 16% share price gain to US$6.26, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 17x in the Pharmaceuticals industry in the US. Total loss to shareholders of 30% over the past three years. Reported Earnings • May 08
First quarter 2021 earnings released: EPS US$0.20 (vs US$0.69 in 1Q 2020) The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$717.9m (down 13% from 1Q 2020). Net income: US$47.1m (down 70% from 1Q 2020). Profit margin: 6.6% (down from 19% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Recent Insider Transactions Derivative • Apr 09
Chairman exercised options and sold US$1.4m worth of stock On the 6th of April, Paul Campanelli exercised options to acquire 188k shares at no cost and sold these for an average price of US$7.37 per share. This trade did not impact their existing holding. Since June 2020, Paul's direct individual holding has increased from 1.07m shares to 1.27m. Company insiders have collectively sold US$2.3m more than they bought, via options and on-market transactions in the last 12 months. Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment deteriorated over the past week After last week's 19% share price decline to US$6.90, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 18x in the Pharmaceuticals industry in the US. Total returns to shareholders of 22% over the past three years. Recent Insider Transactions • Mar 16
Independent Director recently sold US$150k worth of stock On the 15th of March, Shane Cooke sold around 17k shares on-market at roughly US$8.65 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Valuation Update With 7 Day Price Move • Mar 05
Investor sentiment deteriorated over the past week After last week's 26% share price decline to US$6.89, the stock is trading at a trailing P/E ratio of 6.4x, down from the previous P/E ratio of 8.6x. This compares to an average P/E of 27x in the Pharmaceuticals industry in the US. Total return to shareholders over the past three years is a loss of 2.7%. Price Target Changed • Mar 02
Price target raised to US$7.45 Up from US$6.91, the current price target is an average from 13 analysts. The new target price is close to the current share price of US$7.51. As of last close, the stock is up 32% over the past year. Reported Earnings • Feb 27
Full year 2020 earnings released: EPS US$1.08 (vs US$1.60 loss in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: US$2.90b (flat on FY 2019). Net income: US$247.5m (up US$608.0m from FY 2019). Profit margin: 8.5% (up from net loss in FY 2019). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Analyst Estimate Surprise Post Earnings • Feb 27
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 3.5%. Earnings per share (EPS) also surpassed analyst estimates by 6.0%. Over the next year, revenue is expected to shrink by 4.8% compared to a 29% growth forecast for the Pharmaceuticals industry in the US. Is New 90 Day High Low • Feb 18
New 90-day high: US$10.02 The company is up 88% from its price of US$5.32 on 19 November 2020. The American market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$23.81 per share. Price Target Changed • Feb 12
Price target raised to US$6.91 Up from US$6.45, the current price target is an average from 13 analysts. The new target price is 24% below the current share price of US$9.13. As of last close, the stock is up 47% over the past year. Is New 90 Day High Low • Feb 02
New 90-day high: US$8.34 The company is up 89% from its price of US$4.42 on 03 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$23.81 per share. Price Target Changed • Jan 05
Price target raised to US$6.27 Up from US$5.64, the current price target is an average from 13 analysts. The new target price is 16% below the current share price of US$7.48. As of last close, the stock is up 62% over the past year.